Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Recent Innovations Showcased by Baxter

Baxter International Inc. a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery portfolio of hemostatic and sealing agents. New...

Eli Lilly’s Foundayo™: The Newest GLP-1 Innovation Offered by Ro

Ro, the leading direct-to-patient healthcare company, announced eligible patients can now access Foundayo™ (orforglipron) – Eli Lilly Company's newest oral GLP-1 innovation – on the Ro platform, adding to Ro's already comprehensive formulary of...

Approval and Launch of Nintedanib Capsules

Dexcel Pharma USA is pleased to announce that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, the generic equivalent of...

When Every Beat Matters, BD Helps Clinicians Gain Continuous, Noninvasive Blood Pressure Insight to Eliminate Blind Spots

BD a leading global medical technology company, announced the launch of the HemoSphere Stream™ Module, a new innovation which gives clinicians continuous, noninvasive visibility into patients' blood pressure. The module delivers real-time,...

Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences

Curve Biosciences, the Whole-Body Intelligence™ company, announced the appointment of Amit Singal, M.D., as Chief Medical Officer. A nationally recognized leader in clinical management of liver diseases like cirrhosis, hepatocellular carcinoma,...

Fast-Acting Covalent Protein Drugs Developed from a New High-Throughput Platform

A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A...

Convergent Therapeutics Appoints Michael Rossi to Board

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of prostate cancer, announced the appointment of Michael Rossi to its Board of Directors. Mr. Rossi...

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

Johnson & Johnson a worldwide leader in multiple myeloma therapies, announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of...

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

Merck known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan). Merck’s first-in-class oral...

SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

Clarity Pharmaceuticals a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that yet another participant with mCRPC in the...

PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

PureTech Health plc a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announced that the U.S. Food and Drug Administration (FDA) and European Commission have granted Orphan Drug...

New ECCO data demonstrate that subcutaneous infliximab (Remsima™ SC) recaptures and maintains disease control following a drug holiday

Celltrion, Inc. announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response in most Crohn’s disease (CD) and ulcerative colitis...

China approves Libevitug, first-in-class therapy for hepatitis D

Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated...

Correction — Privo Technologies

Privo Technologies, Inc. announced the successful completion of its Phase 1/2 clinical evaluation of PRV211, a first-in-class intraoperative chemotherapy patch for head and neck cancer patients. The study demonstrated excellent safety outcomes...

HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

HanchorBio, Inc. a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing...

Lansinoh® Launched NaturalWave® Double Electric Breast Pump Featuring Exclusive Flutter Technology for Increased Milk Output

Lansinoh®, a leader in breastfeeding and maternal care for over four decades, announced the launch of the NaturalWave® Double Electric Breast Pump, a next-generation power pump engineered to solve a major gap in the market: helping moms not just...

Ad Hoc Analyses Indicate Enhanced Survival Outcomes with VYLOY™ (zolbetuximab) Combined with Chemotherapy When Common Adverse Events Are Properly Managed

Astellas Pharma U.S., Inc. announced the publication of exploratory ad hoc analyses from the combined Phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies in patients with HER2-negative, CLDN18.2-positive advanced gastric or...

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

Octapharma USA, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new 2-gram presentation of Fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for fibrinogen replacement in patients with acquired...

In Europe, Samsung Bioepis begins the commercialization of BYOOVIZ®, a biosimilar to Lucentis (Ranibizumab)

Samsung Bioepis Co., Ltd. announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen...

Peer-reviewed validation of a 60-channel closed-loop neurostimulation brain implant is published by Nia Therapeutics

Nia Therapeutics announced publication in Brain Stimulation of the first in vivo validation of its Smart Neurostimulation System (SNS), a wireless, implantable brain-computer interface designed for closed-loop treatment of memory disorders. The...